Diferencia entre revisiones de «Bismuth subsalicylate»

(Prepared the page for translation)
(Marked this version for translation)
 
Línea 2: Línea 2:
<translate>
<translate>


==Administration==
==Administration== <!--T:1-->


<!--T:2-->
*Type: Anti-[[Special:MyLanguage/diarrhea|diarrhea]]l
*Type: Anti-[[Special:MyLanguage/diarrhea|diarrhea]]l
*Dosage Forms:
*Dosage Forms:
Línea 10: Línea 11:




==Adult Dosing==
==Adult Dosing== <!--T:3-->


<!--T:4-->
*[[Special:MyLanguage/Diarrhea|Diarrhea]], gas, indigestion, heartburn, [[Special:MyLanguage/nausea|nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
*[[Special:MyLanguage/Diarrhea|Diarrhea]], gas, indigestion, heartburn, [[Special:MyLanguage/nausea|nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
*[[Special:MyLanguage/H. pylori|H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist
*[[Special:MyLanguage/H. pylori|H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist




==Pediatric Dosing==
==Pediatric Dosing== <!--T:5-->


<!--T:6-->
*<3y: safety/efficacy not established
*<3y: safety/efficacy not established
*2-6y: 87mg PO q30-60m PRN
*2-6y: 87mg PO q30-60m PRN
Línea 25: Línea 28:




==Special Populations==
==Special Populations== <!--T:7-->




===[[Special:MyLanguage/Drug pregnancy categories|Pregnancy Rating]]===
===[[Special:MyLanguage/Drug pregnancy categories|Pregnancy Rating]]=== <!--T:8-->


<!--T:9-->
*Category C, Category D in 3rd trimester
*Category C, Category D in 3rd trimester




===Lactation risk===
===Lactation risk=== <!--T:10-->


<!--T:11-->
*Salicylates enter breastmilk; use with caution
*Salicylates enter breastmilk; use with caution




===Renal Dosing===
===Renal Dosing=== <!--T:12-->


<!--T:13-->
*Caution: overdose may cause nephrotoxicity
*Caution: overdose may cause nephrotoxicity




===Hepatic Dosing===
===Hepatic Dosing=== <!--T:14-->




==Contraindications==
==Contraindications== <!--T:15-->


<!--T:16-->
*Allergy to class/drug
*Allergy to class/drug
*Infectious diarrhea (fever)
*Infectious diarrhea (fever)
Línea 54: Línea 61:




==Adverse Reactions==
==Adverse Reactions== <!--T:17-->




===Serious===
===Serious=== <!--T:18-->


<!--T:19-->
*Duodenal ulcer, GI hemorrhage
*Duodenal ulcer, GI hemorrhage
*Neurotoxicity
*Neurotoxicity
Línea 64: Línea 72:




===Common===
===Common=== <!--T:20-->


<!--T:21-->
*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
*Black stool, melena
*Black stool, melena
Línea 78: Línea 87:




==Pharmacology==
==Pharmacology== <!--T:22-->


<!--T:23-->
*Half-life: Bismuth- 21-72 days, salicylate- 2.5h
*Half-life: Bismuth- 21-72 days, salicylate- 2.5h
*Metabolism: GI tract, liver
*Metabolism: GI tract, liver
Línea 85: Línea 95:




==Mechanism of Action==
==Mechanism of Action== <!--T:24-->


<!--T:25-->
*Bismuth: antimicrobial, anti-inflammatory action
*Bismuth: antimicrobial, anti-inflammatory action
*Salicylate: antisecretory effect
*Salicylate: antisecretory effect




==Comments==
==Comments== <!--T:26-->




==See Also==
==See Also== <!--T:27-->


<!--T:28-->
*[[Special:MyLanguage/Bismuth toxicity|Bismuth toxicity]]
*[[Special:MyLanguage/Bismuth toxicity|Bismuth toxicity]]




==References==
==References== <!--T:29-->


<!--T:30-->
https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10
https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10
<references/>
<references/>


<!--T:31-->
[[Category:Pharmacology]]
[[Category:Pharmacology]]
[[Category:GI]]
[[Category:GI]]
</translate>
</translate>

Revisión actual - 21:25 6 ene 2026

Otros idiomas:

Administration

  • Type: Anti-diarrheal
  • Dosage Forms:
  • Routes of Administration: PO
  • Common Trade Names: Pepto Bismol, Maalox


Adult Dosing

  • Diarrhea, gas, indigestion, heartburn, nausea: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
  • H. pylori: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist


Pediatric Dosing

  • <3y: safety/efficacy not established
  • 2-6y: 87mg PO q30-60m PRN
  • 6-9y: 175mg PO q30-60m PRN
  • 9-12y: 262mg PO q30-60m PRN
  • >12y: adult dose


Special Populations

Pregnancy Rating

  • Category C, Category D in 3rd trimester


Lactation risk

  • Salicylates enter breastmilk; use with caution


Renal Dosing

  • Caution: overdose may cause nephrotoxicity


Hepatic Dosing

Contraindications

  • Allergy to class/drug
  • Infectious diarrhea (fever)
  • von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia
  • In pediatric patients; chicken pox or influenza (risk of Reye syndrome)


Adverse Reactions

Serious

  • Duodenal ulcer, GI hemorrhage
  • Neurotoxicity
  • Renal failure


Common

  • Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
  • Black stool, melena
  • URI, sinusitis
  • Asthenia
  • Discolored tongue, taste perversion
  • Headache, dizziness
  • Paresthesia
  • Anxiety, depression
  • Tinnitus
  • Muscle spasm


Pharmacology

  • Half-life: Bismuth- 21-72 days, salicylate- 2.5h
  • Metabolism: GI tract, liver
  • Excretion: Bismuth- feces, salicylate- urine


Mechanism of Action

  • Bismuth: antimicrobial, anti-inflammatory action
  • Salicylate: antisecretory effect


Comments

See Also


References

https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10

Obtenido de «https://www.wikem.org/w/index.php?title=Bismuth_subsalicylate&oldid=380140»